(Adnkronos) - Con un’incidenza di 0.5 - 4.2 casi per milione di persone e una prevalenza tra i 10-14 casi per milione, la granulomatosi eosinofilica con poliangite (Egpa) è una malattia rara che interessa i vasi sanguigni di piccole e medie dimensioni, coinvolgendo più organi. È una malattia subdola e per la diagnosi ci possono volere tra i 7 e i 10 anni. Dell’Egpa e dei nuovi approcci terapeutici se ne è parlato all’incontro stampa organizzato da Gsk a Milano, “Egpa: opportunità di trattamento con mepolizumab e ruolo dello pneumologo”.
Category
🗞
NewsTranscript
00:00With an incidence of 0.5 and 4.2 cases per million people and a prevalence between 10 and 14 cases per million,
00:12granulomatosis is eosinophilic with polyangiitis and GPA,
00:17it is a rare disease that affects blood vessels of small, medium and large sizes involving several organs.
00:23It is a subdual disease and for this reason, for diagnosis, it can take between 7 and 10 years.
00:28Alarm bell, the unmeasured increase of eosinophils, cells of the immune system.
00:34They are normally patients who have asthma for years, they have chronic rhinosinusitis,
00:40often with polyposis, they are also operated 2-3 times.
00:44At a certain point there is an important increase of eosinophils
00:49and therefore one of the important things to say is to always check the eosinophils,
00:56an hemochrome with the formula to see if they are in normal form or increased.
01:02Because if they increase in a really important way, like over 5, 10,000, 15,000,
01:08they can then infiltrate the organs and therefore there becomes the problem.
01:13The GPA, already known as Churg-Strauss syndrome, was dedicated to the EGPA press conference,
01:20an opportunity for treatment with mepolizumab and the role of the pneumologist,
01:25organized in Milan by GSK, an appointment in which new therapeutic approaches were also discussed.
01:31The advent of new therapies, extremely targeted, such as mepolizumab,
01:36which blocks circulating interleukin-5, allows us to target in an extremely specific way
01:42the path of type 2 inflammation, rapidly reducing the circulating and tissueal eosinophil,
01:48therefore checking all those eosinophilic manifestations
01:52that characterize the relapses that these patients have.
01:55This allows us to significantly reduce the exposure to cortisone
02:00and improve the quality of life of these patients.
02:03The impact of the EGPA on the life of patients involves both the physical and psychological level,
02:09it is essential for them to have a perspective of care.
02:12Today, patients can live a life as normal as possible,
02:17no matter how difficult the term may be,
02:21and certainly they have a very different therapeutic and care horizon compared to a while ago.